From Mind To Market - Boehringer Ingelheim

16
We have the technology
Aseptic filling, lyophilization, labelling and packaging
With its two sites for aseptic processing, the
corporation has developed efficient methods
of aseptic filling, lyophilization, labelling
and packaging. Boehringer Ingelheim Pharma
GmbH & Co. KG in Germany has one of the
most modern and one of the largest facilities
for New Biological Entities (NBEs) in the world.
In addition to our recognition as a world leader
in this field, Ben Venue Laboratories facility
in Bedford, Ohio, USA, has received an uninter-
rupted series of development and manufacturing
contracts from 1967 up to date. Our experience
assures fast product and technology transfers,
enabling a smooth transition from the clinical
to the commercial phase.
Today, Boehringer Ingelheim has more than
twenty lyophilizers, with capacities ranging from
0.6 to 33 m2 of shelf area, making it one of the
largest facilities of its kind. All the lyophilizers are
computer controlled and optimized to enhance
drying rates and shorten cycles.
All plants are equipped and staffed to perform
full service under proven compliance.
Developmental capabilities include technology
platforms for therapeutic proteins, monoclonal
antibodies and nonviral vector systems for gene
therapy as vials, pre-filled syringes, and inhalative
devices.